BioSyent (CVE:RX) Stock Price Crosses Above 50 Day Moving Average – Here’s Why

BioSyent Inc. (CVE:RX)’s share price crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of C$11.36 and traded as high as C$11.45. BioSyent shares last traded at C$11.00, with a volume of 6,223 shares traded.

BioSyent Stock Performance

The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. The firm’s fifty day moving average price is C$11.36 and its 200-day moving average price is C$10.75. The firm has a market cap of C$129.34 million, a price-to-earnings ratio of 18.60 and a beta of 0.93.

Insider Activity

In other BioSyent news, Senior Officer Robert Joseph March sold 4,775 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75. Also, insider FAX Capital Corp. sold 230,800 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of C$11.12, for a total transaction of C$2,566,496.00. Insiders have sold 349,144 shares of company stock valued at $3,903,370 in the last ninety days. 33.65% of the stock is currently owned by company insiders.

About BioSyent

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.